Gena Wang
Stock Analyst at Barclays
(3.12)
# 1,267
Out of 4,983 analysts
219
Total ratings
44.37%
Success rate
1.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $58 → $78 | $61.32 | +27.21% | 12 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $53 → $71 | $49.76 | +42.68% | 3 | Sep 3, 2025 | |
| KOD Kodiak Sciences | Maintains: Underweight | $4 → $7 | $9.33 | -24.97% | 9 | Aug 14, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $50 → $37 | $9.26 | +299.57% | 7 | Aug 8, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $59 → $62 | $41.44 | +49.61% | 4 | Aug 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $42 → $56 | $61.19 | -8.48% | 17 | Aug 6, 2025 | |
| BEAM Beam Therapeutics | Maintains: Equal-Weight | $25 → $21 | $22.91 | -8.34% | 10 | Aug 6, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $40 → $31 | $24.84 | +24.80% | 10 | Aug 4, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $329 → $460 | $461.24 | -0.27% | 8 | Aug 1, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Equal-Weight | $10 → $22 | $18.10 | +21.55% | 15 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $46 | $59.69 | -22.94% | 16 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $5.41 | +84.84% | 7 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $5 | $0.51 | +872.38% | 4 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $3.16 | +26.58% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $38 | $6.69 | +468.01% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $7.75 | +41.94% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $4.86 | +537.86% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $26 | $12.27 | +111.90% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $435 → $467 | $391.36 | +19.33% | 17 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.83 | +6.01% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $53.94 | +59.44% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $29.48 | +174.76% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $34.34 | +173.73% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $15.84 | -43.18% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $18.09 | +38.20% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $7.32 | +145.90% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $4.52 | +99.12% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.68 | +4,741.55% | 1 | Jan 6, 2017 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Overweight
Price Target: $58 → $78
Current: $61.32
Upside: +27.21%
Cytokinetics
Sep 3, 2025
Maintains: Overweight
Price Target: $53 → $71
Current: $49.76
Upside: +42.68%
Kodiak Sciences
Aug 14, 2025
Maintains: Underweight
Price Target: $4 → $7
Current: $9.33
Upside: -24.97%
REGENXBIO
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $9.26
Upside: +299.57%
Avidity Biosciences
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $41.44
Upside: +49.61%
CRISPR Therapeutics AG
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $61.19
Upside: -8.48%
Beam Therapeutics
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $22.91
Upside: -8.34%
Moderna
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $40 → $31
Current: $24.84
Upside: +24.80%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $329 → $460
Current: $461.24
Upside: -0.27%
Sarepta Therapeutics
Jul 30, 2025
Upgrades: Equal-Weight
Price Target: $10 → $22
Current: $18.10
Upside: +21.55%
Jul 29, 2025
Maintains: Equal-Weight
Price Target: $42 → $46
Current: $59.69
Upside: -22.94%
May 16, 2025
Maintains: Overweight
Price Target: $15 → $10
Current: $5.41
Upside: +84.84%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $5
Current: $0.51
Upside: +872.38%
May 13, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $3.16
Upside: +26.58%
May 9, 2025
Maintains: Overweight
Price Target: $45 → $38
Current: $6.69
Upside: +468.01%
May 7, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $7.75
Upside: +41.94%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $4.86
Upside: +537.86%
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $12.27
Upside: +111.90%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $391.36
Upside: +19.33%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.83
Upside: +6.01%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $53.94
Upside: +59.44%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $29.48
Upside: +174.76%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $34.34
Upside: +173.73%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $15.84
Upside: -43.18%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $18.09
Upside: +38.20%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $7.32
Upside: +145.90%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $4.52
Upside: +99.12%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.68
Upside: +4,741.55%